Key facts
- This page summarizes Lou Reese's Form 4 filing for Vaxxinity, Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 05 Apr 2023, 16:48.
Lou Reese - 07 Mar 2023 Form 4 Insider Report for Vaxxinity, Inc.
- Reporting relationship
- Executive Chairman., Director
- Issuer ticker
- N/A
- Reported as of
- 07 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Apr 2023, 16:48:09 UTC
- Prior SEC filing
- 21 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rene Paula Molina as Attorney-in-Fact for Lou Reese
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lou Reese filed Form 4 for Vaxxinity, Inc. on 05 Apr 2023.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VAXX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +620,000
- Change %
- Price
- $0.000000
- Shares after
- 620,000
- Date
- 07 Mar 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 620,000
- Exercise price
- $2.29
- Footnotes
- F1
VAXX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +61,607
- Change %
- Price
- $0.000000
- Shares after
- 61,607
- Date
- 07 Mar 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 61,607
- Exercise price
- $2.29
- Footnotes
- F2
VAXX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +301,188
- Change %
- Price
- $0.000000
- Shares after
- 301,188
- Date
- 07 Mar 2023
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 301,188
- Exercise price
- $2.29
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 48 equal monthly installments beginning on March 7, 2023.
Footnote F2
The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options are fully vested upon issuance. This one-time option grant was made in lieu of an annual cash bonus payment to Mr. Reese.
Footnote F3
The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 12 equal monthly installments beginning on January 1, 2023. The one-time option grant was made in consideration of Mr. Reese waiving his salary for fiscal years 2022 and 2023.
SEC remarks
Executive Chairman.